GSK's Witty Calls Out Pricing as a Threat to EU Innovation
By Nuala Moran
Staff Writer
Staff Writer
Wednesday, August 8, 2012
LONDON – Andrew Witty, CEO of GlaxoSmithKline plc and president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), hit out at austerity-driven pricing and reimbursement policies in an open letter to European heads of state delivered on Monday.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries,
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-877-857-2477
Outside of the US
Tel. +44-203-684-1796
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-877-857-2477
Outside of the US
Tel. +44-203-684-1796
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter